Assays typically survey driver mutations relevant to lung cancer biology and therapy resistance – such as KRAS, PIK3CA and EGFR – and clonal‐haematopoiesis (CH) genes like DNMT3A and TET2, which are monitored to distinguish tumour DNA from age‐related background variants.219, 220. This evidence concerns the gene KRAS and lung cancer.